Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

<h4>Background</h4>A vaccine against HIV is widely considered the most effective and sustainable way of reducing new infections. We evaluated the safety and impact of boosting with subtype C CN54rgp140 envelope protein adjuvanted in glucopyranosyl lipid adjuvant (GLA-AF) in Tanzanian vol...

Full description

Bibliographic Details
Main Authors: Agricola Joachim, Asli Bauer, Sarah Joseph, Christof Geldmacher, Patricia J Munseri, Said Aboud, Marco Missanga, Philipp Mann, Britta Wahren, Guido Ferrari, Victoria R Polonis, Merlin L Robb, Jonathan Weber, Roger Tatoud, Leonard Maboko, Michael Hoelscher, Eligius F Lyamuya, Gunnel Biberfeld, Eric Sandström, Arne Kroidl, Muhammad Bakari, Charlotta Nilsson, Sheena McCormack
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0155702

Internet

https://doi.org/10.1371/journal.pone.0155702

Similar Items